Collaboration Agreements - Alexion – 2014 Strategic Alliance in Rare Diseases (Details) |
1 Months Ended | 3 Months Ended | 12 Months Ended | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Jan. 31, 2014
USD ($)
candidate
|
Dec. 31, 2019
USD ($)
|
Sep. 30, 2019
USD ($)
|
Jun. 30, 2019
USD ($)
|
Mar. 31, 2019
USD ($)
|
Dec. 31, 2018
USD ($)
|
Sep. 30, 2018
USD ($)
|
Jun. 30, 2018
USD ($)
|
Mar. 31, 2018
USD ($)
|
Dec. 31, 2019
USD ($)
|
Dec. 31, 2018
USD ($)
|
Dec. 31, 2017
USD ($)
|
|
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | ||||||||||||
| Deferred revenue recognized | $ 51,987,000 | |||||||||||
| Collaboration revenue | $ 14,055,000 | $ 17,046,000 | $ 13,083,000 | $ 16,025,000 | $ 35,421,000 | $ 41,757,000 | $ 28,851,000 | $ 29,039,000 | 60,209,000 | $ 135,068,000 | $ 205,825,000 | |
| Deferred revenue | 199,528,000 | 240,924,000 | 199,528,000 | 240,924,000 | ||||||||
| Collaboration revenue | ||||||||||||
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | ||||||||||||
| Collaboration revenue | 42,803,000 | 76,519,000 | 146,953,000 | |||||||||
| 2014 Alexion Agreements | ||||||||||||
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | ||||||||||||
| Upfront cash payments | $ 100,000,000 | |||||||||||
| Proceeds from equity investment | $ 25,000,000 | |||||||||||
| Number of product candidates | candidate | 10 | |||||||||||
| Arrangement term | 10 years | |||||||||||
| Deferred revenue recognized | 70,300,000 | |||||||||||
| Deferred revenue | $ 0 | $ 0 | 0 | $ 0 | ||||||||
| 2014 Alexion Agreements | Collaboration revenue | ||||||||||||
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | ||||||||||||
| Collaboration revenue | $ 0 | $ 74,400,000 | ||||||||||